Arena Pharma (ARNA) Tops Q4 Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Arena Pharma (ARNA) PT Raised to $63 at Credit Suisse
February 27, 2019 8:02 AM ESTCredit Suisse analyst Martin Auster raised the price target on Arena Pharma (NASDAQ: ARNA) to $63.00 (from $61.00) while maintaining a Outperform rating.
... MoreArena Pharma (ARNA) PT Raised to $79 at RBC Capital
February 27, 2019 6:43 AM ESTRBC Capital analyst Kennen MacKay raised the price target on Arena Pharma (NASDAQ: ARNA) to $79.00 (from $70.00) while maintaining a Outperform rating.
Flush with cash, ARNA positions to execute in the clinic in 2019, MacKay comments.
... More